Melphalan Tillomed

Melphalan, the active ingredient in Melphalan Tillomed, is an alkylating agent presented as an injectable formulation for intravenous use. It is employed in the treatment of certain hematologic malignancies and solid tumors, including multiple myeloma, ovarian cancer, melanoma and chronic lymphocytic leukemia, typically in adult oncology patients.

GNH USA supplies Melphalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution, including batch release certificates and stability data.

Melphalan is an alkylating chemotherapy agent used in several cancer treatment pathways.

- Multiple myeloma: reduces malignant plasma cell proliferation and improves survival outcomes. - Ovarian cancer: contributes to tumor cell kill when combined with other chemotherapeutics. - Melanoma: provides cytotoxic activity against rapidly dividing melanoma cells. - Chronic lymphocytic leukemia: induces DNA cross‑linking leading to leukemic cell apoptosis.

Melphalan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: decreased white blood cells, red cells and platelets. - Fatigue: generalized tiredness affecting daily activities. - Mucositis: inflammation and ulceration of the oral mucosa.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related leukemia or other cancers. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases. - Severe infection: due to profound neutropenia leading to sepsis.

Prior to initiating melphalan therapy, several safety considerations should be reviewed. - Baseline blood counts: obtain complete blood count to assess marrow reserve. - Renal function: evaluate creatinine clearance as dosing may require adjustment. - Hepatic status: monitor liver enzymes for potential impairment. - Concomitant medications: review other myelosuppressive agents to avoid additive toxicity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Other alkylating agents: combined use markedly increases myelosuppression risk. - High‑dose radiation therapy: may exacerbate tissue damage and hematologic toxicity.

Moderate Interactions (Monitor Closely): - Antifolate drugs (e.g., methotrexate): may enhance cytotoxic effects and require dose adjustments. - CYP450 inducers (e.g., phenobarbital): could reduce melphalan plasma levels, diminishing effectiveness.